Erasca Faces Legal Challenge Over IP Claims
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: PRnewswire
- Stock Price Plunge: Erasca, Inc. (NASDAQ:ERAS) saw its shares plummet by $9.25 (-48%) on April 28, 2026, after facing a legal challenge from competitor Revolution Medicines regarding intellectual property claims, resulting in a loss of over $2.8 billion in market capitalization in just one day, indicating a severe erosion of market confidence in its lead product ERAS-0015.
- Legal Investigation Launched: The national shareholder rights law firm Hagens Berman has initiated an investigation into whether Erasca misled investors about the viability of its ERAS-0015 intellectual property, urging affected investors to come forward, suggesting potential broader legal ramifications for the company.
- Competitor Allegations: Revolution Medicines has accused Erasca of infringing on its patents with ERAS-0015 and demanded an immediate halt to its sale and importation in the U.S., highlighting the intensifying competition in the oncology sector and posing significant challenges to Erasca's market position.
- Investor Confidence Eroded: Despite Erasca's assurances regarding its intellectual property protection on March 12, 2026, the subsequent legal challenge has cast doubt on these claims, potentially leading to diminished investor confidence that could adversely affect the company's future financing and market performance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ERAS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ERAS
Wall Street analysts forecast ERAS stock price to fall
8 Analyst Rating
6 Buy
1 Hold
1 Sell
Moderate Buy
Current: 13.180
Low
2.00
Averages
5.50
High
11.00
Current: 13.180
Low
2.00
Averages
5.50
High
11.00
About ERAS
Erasca, Inc. is a clinical-stage precision oncology company. The Company is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The Company has assembled RAS/MAPK pathway-focused pipeline in the industry, consisting of modality-agnostic programs aligned with its three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes one clinical-stage program (a pan-RAF inhibitor), two IND-enabling stage programs (a pan-RAS molecular glue and a pan-KRAS inhibitor), and an additional discovery-stage program (an EGFR D2/D3 biparatopic antibody). Its lead product candidate is naporafenib, the Company initiated its SEACRAFT-2 pivotal Phase III trial for patients with NRAS-mutated (NRASm) melanoma.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Erasca Faces Legal Challenge Over IP Claims
- Stock Price Plunge: Erasca, Inc. (NASDAQ:ERAS) saw its shares plummet by $9.25 (-48%) on April 28, 2026, after facing a legal challenge from competitor Revolution Medicines regarding intellectual property claims, resulting in a loss of over $2.8 billion in market capitalization in just one day, indicating a severe erosion of market confidence in its lead product ERAS-0015.
- Legal Investigation Launched: The national shareholder rights law firm Hagens Berman has initiated an investigation into whether Erasca misled investors about the viability of its ERAS-0015 intellectual property, urging affected investors to come forward, suggesting potential broader legal ramifications for the company.
- Competitor Allegations: Revolution Medicines has accused Erasca of infringing on its patents with ERAS-0015 and demanded an immediate halt to its sale and importation in the U.S., highlighting the intensifying competition in the oncology sector and posing significant challenges to Erasca's market position.
- Investor Confidence Eroded: Despite Erasca's assurances regarding its intellectual property protection on March 12, 2026, the subsequent legal challenge has cast doubt on these claims, potentially leading to diminished investor confidence that could adversely affect the company's future financing and market performance.
See More
Erasca Faces Legal Challenge Over Intellectual Property Claims
- Stock Price Plunge: Erasca, Inc. saw its shares plummet by $9.25 (-48%) on April 28, 2026, following the announcement of a legal challenge to its intellectual property, resulting in a loss of over $2.8 billion in market capitalization in a single day, indicating a severe erosion of investor confidence in its lead product ERAS-0015.
- Legal Challenge Context: Competitor Revolution Medicines has initiated a legal challenge against Erasca's ERAS-0015, claiming patent infringement and demanding an immediate halt to sales in the U.S., which could have long-term implications for Erasca's market position and competitive strategy.
- Investor Investigation Launched: Hagens Berman law firm has opened an investigation into whether Erasca misled investors regarding the viability of its intellectual property, urging affected investors to come forward, which may further undermine investor confidence and lead to potential legal repercussions for the company.
- Uncertain Product Development Outlook: While ERAS-0015 is considered a potential
See More
Erasca Faces Investor Lawsuit Investigation
- Legal Investigation Initiated: Bragar Eagel & Squire, P.C. is investigating Erasca for potential violations of federal securities laws or other unlawful business practices, indicating significant legal risks for the company.
- Significant Stock Price Drop: On April 28, 2026, Erasca's stock plummeted by $9.25, approximately 48%, from $19.15 to $9.90, severely impacting investor confidence and raising concerns about the company's stability.
- Investor Rights Protection: The law firm encourages all investors who suffered losses in Erasca to reach out, highlighting the potential for a class-action lawsuit, which could further exacerbate market fears regarding the company's future.
- Recommended Next Steps: Shareholders with information or questions are offered free consultations, demonstrating a commitment to investor rights while potentially affecting Erasca's reputation and market performance.
See More
RTW Investments Increases Stake in Erasca
- Increased Holdings: RTW Investments acquired 16,010,524 shares of Erasca in Q1 2026, with an estimated transaction value of $189.23 million, indicating strong confidence in the company's future prospects.
- Market Value Growth: The quarter-end value of Erasca's holdings reached $261.42 million, reflecting an increase of $260.88 million from the previous quarter, driven by both share price appreciation and additional purchases.
- R&D Progress: Erasca's lead program, ERAS-0015, has shown promising early responses in patients with KRAS-driven lung and pancreatic cancers, with the CEO highlighting its potential as a future
See More
RTW Investments Increases Stake in Erasca
- Stake Increase: RTW Investments disclosed in a May 15, 2026 SEC filing that it acquired 16,010,524 shares of Erasca, valued at approximately $189.23 million, indicating strong confidence in the company's prospects.
- Value Growth: As of March 31, 2026, RTW's total stake in Erasca reached $261.42 million, an increase of $260.88 million from the previous quarter, reflecting optimistic market expectations for Erasca's future developments.
- Outstanding Market Performance: Erasca's shares are priced at $12.84, having surged nearly 800% over the past year, significantly outperforming the S&P 500's 28% increase, showcasing growing investor confidence in its research pipeline.
- Strong Financial Position: As of March 2026, Erasca had $408.5 million in cash and marketable securities, expected to fund operations into the second half of 2028, enhancing its research capabilities and competitive position in cancer treatment.
See More
Erasca Under Investigation for Securities Fraud
- Securities Fraud Investigation: Pomerantz LLP is investigating on behalf of Erasca, Inc. investors whether the company has engaged in securities fraud or other unlawful business practices, indicating serious concerns regarding corporate governance.
- Patent Infringement Allegations: On April 28, 2026, Erasca disclosed receiving a letter from Revolution Medicines alleging that its ERAS-0015 infringes a patent and involves trade secret misappropriation, which could lead to legal liabilities.
- Stock Price Plunge: Following the news, Erasca's stock price fell by $9.25, or 48.3%, closing at $9.90 per share, reflecting extreme pessimism in the market regarding the company's future prospects.
- Potential Legal Consequences: Pomerantz LLP, a prominent securities class action firm, indicates that if the allegations are substantiated, Erasca may face substantial damages and reputational harm, impacting its future financing capabilities.
See More
Erasca Faces Legal Challenge Over IP Claims
- Stock Price Plunge: Erasca, Inc. (NASDAQ:ERAS) saw its shares plummet by $9.25 (-48%) on April 28, 2026, after facing a legal challenge from competitor Revolution Medicines regarding intellectual property claims, resulting in a loss of over $2.8 billion in market capitalization in just one day, indicating a severe erosion of market confidence in its lead product ERAS-0015.
- Legal Investigation Launched: The national shareholder rights law firm Hagens Berman has initiated an investigation into whether Erasca misled investors about the viability of its ERAS-0015 intellectual property, urging affected investors to come forward, suggesting potential broader legal ramifications for the company.
- Competitor Allegations: Revolution Medicines has accused Erasca of infringing on its patents with ERAS-0015 and demanded an immediate halt to its sale and importation in the U.S., highlighting the intensifying competition in the oncology sector and posing significant challenges to Erasca's market position.
- Investor Confidence Eroded: Despite Erasca's assurances regarding its intellectual property protection on March 12, 2026, the subsequent legal challenge has cast doubt on these claims, potentially leading to diminished investor confidence that could adversely affect the company's future financing and market performance.
See More
Erasca Faces Legal Challenge Over Intellectual Property Claims
- Stock Price Plunge: Erasca, Inc. saw its shares plummet by $9.25 (-48%) on April 28, 2026, following the announcement of a legal challenge to its intellectual property, resulting in a loss of over $2.8 billion in market capitalization in a single day, indicating a severe erosion of investor confidence in its lead product ERAS-0015.
- Legal Challenge Context: Competitor Revolution Medicines has initiated a legal challenge against Erasca's ERAS-0015, claiming patent infringement and demanding an immediate halt to sales in the U.S., which could have long-term implications for Erasca's market position and competitive strategy.
- Investor Investigation Launched: Hagens Berman law firm has opened an investigation into whether Erasca misled investors regarding the viability of its intellectual property, urging affected investors to come forward, which may further undermine investor confidence and lead to potential legal repercussions for the company.
- Uncertain Product Development Outlook: While ERAS-0015 is considered a potential
See More
Erasca Faces Investor Lawsuit Investigation
- Legal Investigation Initiated: Bragar Eagel & Squire, P.C. is investigating Erasca for potential violations of federal securities laws or other unlawful business practices, indicating significant legal risks for the company.
- Significant Stock Price Drop: On April 28, 2026, Erasca's stock plummeted by $9.25, approximately 48%, from $19.15 to $9.90, severely impacting investor confidence and raising concerns about the company's stability.
- Investor Rights Protection: The law firm encourages all investors who suffered losses in Erasca to reach out, highlighting the potential for a class-action lawsuit, which could further exacerbate market fears regarding the company's future.
- Recommended Next Steps: Shareholders with information or questions are offered free consultations, demonstrating a commitment to investor rights while potentially affecting Erasca's reputation and market performance.
See More
RTW Investments Increases Stake in Erasca
- Increased Holdings: RTW Investments acquired 16,010,524 shares of Erasca in Q1 2026, with an estimated transaction value of $189.23 million, indicating strong confidence in the company's future prospects.
- Market Value Growth: The quarter-end value of Erasca's holdings reached $261.42 million, reflecting an increase of $260.88 million from the previous quarter, driven by both share price appreciation and additional purchases.
- R&D Progress: Erasca's lead program, ERAS-0015, has shown promising early responses in patients with KRAS-driven lung and pancreatic cancers, with the CEO highlighting its potential as a future
See More
RTW Investments Increases Stake in Erasca
- Stake Increase: RTW Investments disclosed in a May 15, 2026 SEC filing that it acquired 16,010,524 shares of Erasca, valued at approximately $189.23 million, indicating strong confidence in the company's prospects.
- Value Growth: As of March 31, 2026, RTW's total stake in Erasca reached $261.42 million, an increase of $260.88 million from the previous quarter, reflecting optimistic market expectations for Erasca's future developments.
- Outstanding Market Performance: Erasca's shares are priced at $12.84, having surged nearly 800% over the past year, significantly outperforming the S&P 500's 28% increase, showcasing growing investor confidence in its research pipeline.
- Strong Financial Position: As of March 2026, Erasca had $408.5 million in cash and marketable securities, expected to fund operations into the second half of 2028, enhancing its research capabilities and competitive position in cancer treatment.
See More
Erasca Under Investigation for Securities Fraud
- Securities Fraud Investigation: Pomerantz LLP is investigating on behalf of Erasca, Inc. investors whether the company has engaged in securities fraud or other unlawful business practices, indicating serious concerns regarding corporate governance.
- Patent Infringement Allegations: On April 28, 2026, Erasca disclosed receiving a letter from Revolution Medicines alleging that its ERAS-0015 infringes a patent and involves trade secret misappropriation, which could lead to legal liabilities.
- Stock Price Plunge: Following the news, Erasca's stock price fell by $9.25, or 48.3%, closing at $9.90 per share, reflecting extreme pessimism in the market regarding the company's future prospects.
- Potential Legal Consequences: Pomerantz LLP, a prominent securities class action firm, indicates that if the allegations are substantiated, Erasca may face substantial damages and reputational harm, impacting its future financing capabilities.
See More
